Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P13010

UPID:
XRCC5_HUMAN

ALTERNATIVE NAMES:
86 kDa subunit of Ku antigen; ATP-dependent DNA helicase 2 subunit 2; ATP-dependent DNA helicase II 80 kDa subunit; CTC box-binding factor 85 kDa subunit; DNA repair protein XRCC5; Ku80; Ku86; Lupus Ku autoantigen protein p86; Nuclear factor IV; Thyroid-lupus autoantigen; X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)

ALTERNATIVE UPACC:
P13010; A8K3X5; Q0Z7V0; Q4VBQ5; Q53HH7; Q7M4N0; Q9UCQ0; Q9UCQ1

BACKGROUND:
The protein XRCC5, widely recognized as Ku80, is integral to the DNA repair process, specifically in the DNA non-homologous end joining (NHEJ) pathway. It acts by binding to DNA ends, recruiting DNA-PK, and facilitating the repair of double-strand breaks. Additionally, XRCC5 plays a role in V(D)J recombination, chromosome translocation, and acts as a 5'-deoxyribose-5-phosphate lyase, crucial for preparing broken DNA ends for ligation.

THERAPEUTIC SIGNIFICANCE:
The critical function of XRCC5 in maintaining genomic stability through its DNA repair role suggests its potential as a therapeutic target. Exploring XRCC5's mechanisms could lead to novel treatments for diseases resulting from impaired DNA repair processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.